Portfolio company
Leyden Labs
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops intranasal antibody sprays to protect people against respiratory viruses by stopping infection at the nasal mucosa.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Halo Therapeutics
This company develops small-molecule antiviral nasal sprays to treat respiratory viral infections for patients suffering from conditions like Covid-19.
Pneumagen
This clinical-stage biotech company develops intranasal antiviral drugs to prevent and treat respiratory tract infections for patients with chronic lung diseases.
Nebu-Flow
The company develops nebuliser technology for pharmaceutical partners to deliver biologic drugs and other formulations to the lungs of patients with respiratory disorders.
RQ Bio
RQ Bio develops long-acting monoclonal antibodies to provide seasonal influenza protection for vulnerable and immunocompromised patients who cannot rely on vaccination alone.
AQUILON PHARMACEUTICALS
The company develops inhaled medicines and nasal sprays for patients with asthma, chronic obstructive pulmonary disease and other respiratory conditions.
ILiAD Biotechnologies
This company develops intranasal vaccines to prevent and treat whooping cough infections in infants, children and adults.
CoVBio
The company develops broad-spectrum vaccines and therapeutic antibodies to protect the global population against coronaviruses and other respiratory viral infections.
Resilient Biotics
This company develops microbiome-derived live biotherapeutics to prevent and treat respiratory diseases in livestock and humans.